Media coverage about VBI Vaccines (NASDAQ:VBIV) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. VBI Vaccines earned a daily sentiment score of 0.23 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 49.4261869891534 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Several equities research analysts recently issued reports on VBIV shares. BidaskClub cut shares of VBI Vaccines from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th. Zacks Investment Research cut shares of VBI Vaccines from a “buy” rating to a “hold” rating in a research report on Saturday, January 6th. BMO Capital Markets started coverage on shares of VBI Vaccines in a research report on Wednesday, November 15th. They issued an “outperform” rating and a $11.00 target price on the stock. Finally, Canaccord Genuity started coverage on shares of VBI Vaccines in a research report on Wednesday, November 1st. They issued a “buy” rating and a $10.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $8.75.
VBI Vaccines (NASDAQ:VBIV) traded up $0.10 on Tuesday, hitting $3.99. 104,300 shares of the company traded hands, compared to its average volume of 110,685. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.97 and a current ratio of 1.03. VBI Vaccines has a twelve month low of $3.04 and a twelve month high of $6.60.
TRADEMARK VIOLATION NOTICE: “VBI Vaccines (VBIV) Receiving Somewhat Positive Media Coverage, Analysis Shows” was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3225751/vbi-vaccines-vbiv-receiving-somewhat-positive-media-coverage-analysis-shows.html.
VBI Vaccines Company Profile
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.